InMed Pharmaceuticals shares are trading lower after the company announced results from its Phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa showed the results for non-wound itch were not statistically significant in favor of INM-755 CBN cream.
Portfolio Pulse from Benzinga Newsdesk
InMed Pharmaceuticals announced that its Phase 2 clinical trial for INM-755 CBN cream, a treatment for symptoms related to epidermolysis bullosa, showed non-statistically significant results for non-wound itch.
June 22, 2023 | 6:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
InMed Pharmaceuticals' stock is trading lower after announcing non-statistically significant results for non-wound itch in its Phase 2 clinical trial for INM-755 CBN cream.
The announcement of non-statistically significant results for non-wound itch in the Phase 2 clinical trial for INM-755 CBN cream is likely to negatively impact InMed Pharmaceuticals' stock price in the short term, as it may raise concerns about the effectiveness of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100